The San Francisco Bay Area is teeming with people, companies, and ideas that aim to shake up the life-sciences status quo. From gene editing to the microbiome, from the frontiers of diagnostics to new interfaces between drugs and digital technology, who is taking the most radical approaches? What are their goals and what is their approach to building great biotech companies? How are the founders working with their leading investors to pursue their disruptive vision?
Join Xconomy as we bring together a group of Bay Area biotech’s top innovators, entrepreneurs, investors, and leaders as we explore the brightest spots on the life sciences horizon.
Confirmed Speakers
Tom Barnes, Chief Scientific Officer, Intellia Therapeutics
Atul Butte, Director of Institute of Computational Health Sciences, UCSF
Colleen Cutcliffe, CEO, WholeBiome
Marcy Darnovsky, Director, Center for Genetics and Society
Peter DiLaura, CEO, Second Genome
Hank Greely, Law Professor, Stanford University
Justin Kao, SVP of Corporate Development, Operations, and Strategy, Helix
Nina Kjellson, General Partner, Canaan Partners
Edward Lanphier, CEO, Sangamo Biosciences
Andy May, CSO, Caribou Biosciences
Jenny Rooke, Managing Director, Five Prime Ventures
Randy Scott, CEO, Invitae
Follow us on Twitter:
@Xconomy
#xcondisrupt
Schedule:
Registration: 1:00 – 2:00 pm
Program: 2:00 – 5:30 pm
Networking reception: 5:30 – 6:30 pm
View the full agenda here.
*Schedule is subject to change
Registration Information:
Regular Registration: $295
Startup Special: $125
Student: $35
At the Door: $375
